Abstract

- **Aim:** To clarify the mechanism of infliximab treatment in diabetic macular edema (DME) and to provide a new alternative therapy for DME.
- **Methods:** Rats were randomly divided into the control group, the model group and the infliximab treatment group. A diabetic rat model was created. The concentration of TNF-α in the vitreous body was detected by ELISA. The expressions of B-Raf, p38, claudin-1 and occludin in the retina were detected by Western blot. The integrity of the blood retinal barrier (BRB) was measured using Evan’s blue as a tracer.
- **Results:** After three months and six months of the diabetic rat model, the vitreous TNF-α level in the model group was higher than that of the control group. The differences among the three groups were statistically significant (at 3mo, $F=447.946$, $P<0.001$; at 6mo, $F=1610.732$, $P<0.001$). The retinal Evans blue leakage in the model group was higher than that of the control group. It was also higher in treated group than that of the control group but was lower than that of the model group. The differences among the three groups were statistically significant at 3mo, $F=139.088$, $P<0.001$ and at 6mo, $F=128.415$, $P<0.001$; occludin at 3mo, $F=92.733$, $P<0.001$ and at 6mo, $F=104.478$, $P<0.001$). The retinal Evans blue leakage in the model group was higher than that of the control group. The differences among the three groups were statistically significant at 3mo, $F=857.098$, $P<0.001; 6$mo, $F=1261.897, P<0.001$).
- **Conclusion:** In a diabetic rat model, infliximab may relieve TNF-α induced BRB breakdown via the B-Raf and p38 signaling pathway.
- **Keywords:** tumor necrosis factor-α; blood-retinal barrier; diabetic macular edema; infliximab; pathogenesis

DOI:10.18240/iJo.2017.12.06

Citation: Xie MS, Zheng YZ, Huang LB, Xu GX. Infliximab relieves blood retinal barrier breakdown through the p38 MAPK pathway in a diabetic rat model. Int J Ophthalmol 2017;10(12):1824-1829

**Introduction**

Diabetic macular edema (DME) is a common progressive complication of diabetes. DME is characterized by the accumulation of fluid in the central retina (macula) and is caused by the blood retinal barrier (BRB) breakdown. DME can lead to serious vision loss in the working-age population, seriously affecting a patient’s daily life and ability to learn and work. The 10-year incidence of DME varies from approximately 20% to 40% among diabetic patients[1]. Focal retinal photocoagulation or grid laser photocoagulation has been the main treatment for DME during the past several decades[1]. However, DME leads to decreased visual acuity and narrowed visual field. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is a new treatment for DME. Repeated intravitreal injections can cause a variety of complications, such as endophthalmitis, vitreous hemorrhaging, retinal detachment, increased intraocular pressure, and arterial thromboembolisms[2-3]. In addition, there are some patients with DME refractory to laser photocoagulation or intravitreal anti-VEGF therapy.

Inflammation plays an important role in the development of DME. The expression of TNF-α is significantly elevated in the serum[4], aqueous humor[5] and vitreous body[6] of patients with...
Diabetic Rat Model

MATERIALS AND METHODS

provide a new, alternative therapy for DME. To clarify the mechanism of infliximab treatment in DME and to treatment was well tolerated. The aim of this study was to 24.3% better than that in placebo-treated eyes. Infliximab with DME, the visual acuity in infliximab-treated eyes was 24.3% better than that in placebo-treated eyes. Infliximab treatment was well tolerated. The aim of this study was to clarify the mechanism of infliximab treatment in DME and to provide a new, alternative therapy for DME.

MATERIALS AND METHODS

Diabetic Rat Model

Healthy male Sprague-Dawley rats with clear ocular media (weight 200±20 g, aged 6wk, Shanghai SLAC Laboratory Animal Co. Ltd, China) were used in this study. This study was performed in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University (Permit Number: 2015-YK-106). Rats were weighed and anesthetized with ketamine hydrochloride/xylazine hydrochloride solution (ketamine hydrochloride 60 mg/kg and xylazine hydrochloride (1.5 mg/100 µL) (K4138, Sigma-Aldrich, St. Louis, MO, USA). Oxybuprocaine (Benoxil, Santen, Japan) was used to provide local anesthesia. Rats were acclimated for 1wk and randomly divided into the control group, the model group and the infliximab treatment group. Baseline blood glucose was measured again 3d after the injection. The rats with streptozotocin (V900890, Sigma-Aldrich, St.). Blood glucose was measured and was freshly prepared prior to each use.

Three and six months after the diabetic model had been established, the concentration of TNF-α in the vitreous body was detected by ELISA according to the manufacturer’s protocol (Rat TNF-α ELISA Kit, Cat. No:RTA00, R & D Inc.).

Detecting the Expression of the B-Raf and p38 Signaling Pathways in the Retina

The frozen retina was isolated. Western blot analysis was performed to detect the expression of the B-Raf and p38 signaling pathways in the retina. The protein concentration was measured with a Bio-Rad assay. Protein samples (30 mg per lane) were separated by SDS-polyacrylamide gel electrophoresis and blotted onto Hybond-N nitrocellulose. After incubation with the B-Raf antibody (1:500, sc-5284, Sigma-Aldrich, St.) and p38 antibody (1:500, sc-7972, Sigma-Aldrich, St.), blots were developed using the Mini PROTEAN Tetra, Cell with Mini Trans-Blot Module system (Bio-Rad, USA) and a Dolphin-Chemi densitometry system (Wealtec, USA).

Detecting the Expression of Claudin-1 and Occludin in the Retina

Western blot analysis was performed to detect the expression of claudin-1 and occludin in the retina. The protein concentrations were measured with a Bio-Rad assay. Protein samples (30 mg per lane) were separated by SDS-polyacrylamide gel electrophoresis and blotted onto Hybond-N nitrocellulose. After incubation with the claudin-1 antibody (1:500, sc-166338, Sigma-Aldrich, St.) and occludin antibody (1:500, sc-271842, Sigma-Aldrich, St.), blots were developed using the Mini PROTEAN Tetra Cell with, Mini Trans-Blot Module (Bio-Rad, USA) and Dolphin-Chemi densitometry system (Wealtec, USA).

Detecting Blood Retinal Barrier Integrity Using Evan’s Blue as a Tracer

Three and six months after the diabetic model had been established, the integrity of the BRB was quantitatively measured using Evan’s blue as a tracer. The procedure for the quantitative measurement of BRB breakdown has been previously reported[16]. Evan’s blue dye (206334, Sigma-Aldrich, St.) was prepared by dissolving it in normal saline (30 mg/mL). The dye concentration in the extracts was calculated from a standard curve of Evan’s blue in formamide. Retinal Evan’s blue leakage was expressed in µL plasma×g retinal dry wt⁻¹ h⁻¹.

Statistical Analysis

The data are presented as the mean±SD. The data were analyzed using ANOVA with an LSD-t test for multiple comparisons. P<0.05 was considered statistically significant.

RESULTS

Detecting the TNF-α Concentrations in the Vitreous Body

Three and six months after the diabetic model had been established, the concentration of TNF-α in the vitreous body of the model group was higher than that of the control group. The
concentration of TNF-α in the vitreous body of the treatment group was higher than that of the control group but was lower than that of the model group. The differences among the three groups were statistically significant (at 3mo, $F=857.098$, $P<0.001$; at 6mo, $F=1261.897$, $P<0.001$) (Figure 1).

Detecting the Expression of the B-Raf and p38 Signaling Pathways in the Retina Three and six months after the diabetic model had been established, the expression of the B-Raf and p38 in the retina of the model group was higher than that of the control group. The expression of the B-Raf and p38 in the treatment group was higher than that of the control group but was lower than that of the model group. The differences among three groups were statistically significant. (B-Raf at 3mo, $F=106.596$, $P<0.001$; at 6mo, $F=200.681$, $P<0.001$; p38 at 3mo, $F=41.662$, $P<0.001$; at 6mo, $F=67.979$, $P<0.001$) (Figures 2 and 3).

Detecting the Expression of Claudin-1 and Occludin in the Retina Three and six months after the diabetic model had been established, the expression of claudin-1 and occludin in the retina of the model group was lower than that of the control group. The expression of claudin-1 and occludin in the treatment group was lower than that of the control group but was higher than that of the model group. The differences among the three groups were statistically significant (claudin-1 at 3mo, $F=139.088$, $P<0.001$; at 6mo, $F=128.415$, $P<0.001$; occludin at 3mo, $F=92.733$, $P<0.001$; at 6mo, $F=104.478$, $P<0.001$) (Figures 4 and 5).

Detecting Blood Retinal Barrier Integrity Using Evan’s Blue as a Tracer Three and six months after the diabetic model had been established, the retinal Evan’s blue leakage in the model group was higher than that in the control group. The retinal Evan’s blue leakage in the treatment group was higher than that in the control group but was lower than that in the model group. The differences among the three groups were statistically significant (at 3mo, $F=447.946$, $P<0.001$; at 6mo, $F=1610.732$, $P<0.001$) (Figure 6).

DISCUSSION

In this study, we found that TNF-α increased after diabetes was induced. TNF-α is an important inflammatory cytokine that is involved in systemic inflammation. TNF-α is mainly produced by activated macrophages, natural killer cells, T lymphocytes, mast cells, eosinophils, neutrophils, neurons and other cell types. The expression of monocyte chemotactic protein-1 (MCP-1) is increased in patients with proliferative diabetic retinopathy. MCP-1 can recruit monocytes, neutrophils, lymphocytes, macrophages and dendritic cells. The expression of TNF-α is significantly elevated in the serum and aqueous humor and vitreous body of patients with diabetes mellitus. TNF-α has a strongly inflammatory effect and can recruit neutrophils, T lymphocytes and macrophages to inflammatory sites. TNF-α also participates in the activation of T lymphocytes, stimulates macrophage phagocytosis and synthesizes other cytokines, involved in the inflammatory response. TNF-α acts on retinal vascular endothelial cells and retinal pigment epithelial cells, to increase the permeability of the retinal barrier, leading to increased retinal leakage of Evan’s blue. The retina is separated from the blood stream via two barriers: the inner BRB and the outer BRB. The inner BRB is formed by retinal capillary endothelial cells. The outer BRB is formed by the retinal pigment epithelium. The BRB is a physiological barrier that regulates ion, protein and water flux into and out of the retina. These barrier characteristics are formed by tight junctions. Occludin and claudin are integral proteins of tight junctions. Our study found that the expression of claudin-1 and occludin in the model group was decreased. This suggests that the tight junctions in the retina of the model group were damaged. Consequently, the retinal Evan’s blue leakage in the model group increased. TNF-α might also promote apoptosis and retinal microvascular cell loss in type 1 and type 2 models of diabetic retinopathy.

Infliximab relieves blood retinal barrier breakdown

Figure 1 The concentration of TNF-α in the vitreous body

Figure 2 The expression of B-Raf in the retina
Infliximab can relieve BRB breakdown. Blocking TNF-α activity is a standard treatment for autoimmune diseases. Infliximab is an FDA approved treatment for rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis and psoriasis. In addition, infliximab is widely used for treating other inflammatory diseases such as uveitis, inflammatory bowel disease and pouchitis. Infliximab is an anti-TNF-α monoclonal antibody. It blocks the inflammatory effect induced by TNF-α. Our study found that the expression of claudin-1 and occludin in the infliximab treatment group was lower than that in the control group but was higher than that in the model group. The retinal Evan’s blue leakage in the infliximab treatment group was higher than that of the control group but was lower than that in the model group. This suggested that infliximab protected the retinal tight junctions from damage. Therefore, the retinal Evan’s blue leakage was decreased in the infliximab treatment group, suggesting that infliximab prevents TNF-α induced inflammation and thereby alleviates BRB breakdown.

Infliximab may prevent TNF-α induced inflammation via the B-Raf and p38 signaling pathways. TNF-α binds to the TNF-α receptor and this cross-communication activates signaling pathways, such as B-Raf, p38, NF-κB, JNK, ERK, PI3K/
Infliximab relieves blood retinal barrier breakdown

Akt and MAPK. Then, TNF-α activates many transcription factors, leading to the transcription of many proteins involved in the inflammatory response, cell survival, differentiation and proliferation[17-21,31]. TNF-α binding to its receptor induces a variety of biological effects, such as stimulation the acute phase response, which leads to an increase in C-reactive protein and other inflammatory mediators. The B-Raf and p38 signaling pathways are involved in many inflammatory diseases such as neuroinflammation[32], periodontitis[33] and rheumatoid arthritis[34]. We found that the expression of p38 and B-Raf in the infliximab treatment group was higher than that in the control group but was lower than that in the model group. This suggests that infliximab may prevent TNF-α induced inflammations via the B-Raf and p38 signaling pathways.

The effect of infliximab was first observed 1h after the intravenous injection. The serum level peaked 3d after the injection and the efficacy of infliximab lasted for 8wk. This avoided the complications inherent to repeated intravitreal injections. In addition, infliximab can restore glucose homeostasis[35] and can treat the refractory ulcerative necrobiosis lipoidica diabeticorum[36].

In summary, we found that the expression of TNF-α and the breakdown of BRB were increased in a diabetic rat model. Infliximab may relieve TNF-α induced BRB breakdown via the B-Raf and p38 signaling pathways.

ACKNOWLEDGEMENTS

Foundation: Supported by Fujian Provincial Health and Family Planning Commission (No.2014-ZQN-ZD-16). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest: Xie MS, None; Zheng YZ, None; Huang LB, None; Xu GX, None.

REFERENCES


